Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 1, 1999, Pages 15-21

  Wolter, Joanne M ^a   Bowler, S D ^b   McCormack, J G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER ADULT HOSPITAL   (Australia)

Author keywords

Antibiotics; Cystic fibrosis; Pseudomonas aeruginosa; Susceptibility testing

Indexed keywords

AMIKACIN; AZTREONAM; CARBENICILLIN; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEZLOCILLIN; NORFLOXACIN; PIPERACILLIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CLINICAL ARTICLE; COMORBIDITY; CYSTIC FIBROSIS; DRUG CHOICE; DRUG POTENCY; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS;

EID: 0033053385     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb01583.x     Document Type: Article

References (29)

1. 1. Regelmann WE, Elliott GR, Wareick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141: 914-21.
2. 2. Gold R, Carpenter S, Heurter H, Corey M, Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1997; 111: 907-13.
3. 3. Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-pseudomonal therapy warranted in acute respiratory exacerbations in children in cystic fibrosis? J Pediatr 1980; 97: 144-7.
4. 4. Govan JRW, Doherty C, Glass S. Rational parameters for antibiotic therapy in patients with cystic fibrosis. Infection 1987; 15: 300-7.
5. 5. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132: 761-5.
6. 6. Schryvers AB, Ogunariwo J, Chamberland S, Godfrey AJ, Rabin HR, Bryan LE. Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis. Antimicrob Agents Chemother 1987; 31: 1438-9.
7. 7. Smith AL, Redding G, Doershuk C et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988; 112: 547-54.
8. 8. Bosso J, Black PG, Matsen JM. Efficacy of aztreonam in pulmonary exacerbation of cystic fibrosis. Pediatr Infect Dis J 1987; 6: 393-7.
9. 9. Bingen E, Denamur E, Picard B et al. Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1992; 11: 432-7.
10. 10. Glass S., Hayward C, Govan JRW. Serum C-reactive protein in assessment of pulmonary exacerbations and antimicrobial therapy in cystic fibrosis. J Paediatr 1988; 113: 76-9.
11. 11. Reed MD, Stern RC, O'Brien C, Crenshaw D, Blumer JL. Randomised double-blind evaluation of ceftazidime dose ranging in hospitalised patients with cystic fibrosis. Antimicrob Agents Chemother 1987; 31: 698-702.
12. 12. Reed MD, Myers CM, Klinger JD, Yamashita TS, Blumer JL. Therapeutic evaluation of piperacillin for acute respiratory exacerbations in cystic fibrosis. Pediatr Pulmonol 1987; 3: 101-9.
13. 13. Smith AL. Antibiotic resistance is not relevant in infections in cystic fibrosis. Pediatr Pulmonol 1990; 9: S5-93.
14. 14. Weiss K, Lapointe JR. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 2411-4.
15. 15. Wolter JM, Kotsiou G, McCormack JG. Mixed morphotype testing of Pseudomonas aeruginosa cultures from cystic fibrosis patients. J Med Microbiol 1995; 42: 220-4.
16. 16. Wolter JM, Bowler SD, McCormack JG, Nolan PJ. Home intravenous therapy in cystic fibrosis - a prospective randomised trial examining clinical, quality of life and cost aspects. Eur Respir J 1997; 10: 896-900.
17. 17. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-8.
18. 18. Saiman L, Mehar F, Niu WW et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23: 532-7.
19. 19. Fyfe JAM, Govan JRW. Chromosomal loci associated with antibiotic hypersensitivity in pulmonary isolates of Pseudomonas aeruginosa. J Gen Microbiol 1984; 130: 825-34.
20. 20. Gravert C, Schulz E, Sack K. Ceftazidime in intensive care medicine and haemofiltration. J Antimicrob Chemother 1983; 12 Suppl. A: 177-80.
21. 21. Norrby SR, Finch RG, Glaeser M, European Study Group. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. J Antimicrob Chemother 1993; 31: 927-37.
22. 22. Keresmar CM, Stern RC, Reed MD, Myers CM, Murdell D, Blumer JL. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother 1983; 12 SA: 289-95.
23. 23. Wood PJ, Ioannides-Demos LL, Li SC et al. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996; 51: 369-73.
24. 24. Powell SH, Thompson WL, Luthe MA et al Once-daily vs continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983; 147:918-32.
25. 25. Heininger U, Bowing B, Stehr K, Solbach W. Aminoglycosides in patients with mucovicsidosis and pulmonary exacerbation. Comparison of one or three times daily administration. Klinische Padiatrie 1993; 205: 18-22.
26. 26. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-5.
27. 27. Govan JRW, Brown PH, Maddison J et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
28. 28. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-61.
29. 29. Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992; 47: 6-13.